BeiGene (BGNE)
(Delayed Data from NSDQ)
$138.99 USD
+7.78 (5.93%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $139.12 +0.13 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.99 USD
+7.78 (5.93%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $139.12 +0.13 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Zacks News
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
by Ekta Bagri
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
Top 5 Momentum Picks for January After a Fabulous 2023
by Nalak Das
We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
New Strong Buy Stocks for December 22nd
by Zacks Equity Research
DOYU, STLA, BGNE, LEGH and WTS have been added to the Zacks Rank #1 (Strong Buy) List on December 22, 2023.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
by Ekta Bagri
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
5 Nasdaq Composite Laggards Likely to Gather Pace in 2024
by Nalak Das
We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.
Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for BeiGene, Ltd. (BGNE) points to a 44.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
by Zacks Equity Research
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
Wall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 32.9% upside potential for BeiGene, Ltd. (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate
by Zacks Equity Research
Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
by Zacks Equity Research
Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.
Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)
by Zacks Equity Research
BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.
Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 Weeks
by Zacks Equity Research
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.
Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.
Is a Surprise Coming for BeiGene (BGNE) This Earnings Season?
by Zacks Equity Research
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Down -14.15% in 4 Weeks, Here's Why BeiGene, Ltd. (BGNE) Looks Ripe for a Turnaround
by Zacks Equity Research
BeiGene, Ltd. (BGNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Anika (ANIK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) Q4 earnings call, investors are likely to focus on the sales performance of its Osteoarthritis Pain (OAP) Management, Joint Preservation and Restoration segments.
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively.
Will Top-Line Contraction Affect Altice (ATUS) Q4 Earnings?
by Zacks Equity Research
Altice's (ATUS) top line is likely to decline year over year. Macroeconomic uncertainty, stiff competition, rising programming costs per consumer, and a hefty financial burden likely limit its earning potential.
Will Higher Revenues Benefit Keysight (KEYS) Q1 Earnings?
by Zacks Equity Research
Keysight's (KEYS) top-line performance in the first quarter of fiscal 2023 is likely to benefit from solid demand for its electronic design and test solutions and a robust 5G portfolio.
Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Apexigen, Inc. (APGN) and BeiGene, Ltd. (BGNE) have performed compared to their sector so far this year.